TY - JOUR
T1 - Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition
AU - Travis, Ruth C.
AU - Key, Timothy J.
AU - Allen, Naomi E.
AU - Appleby, Paul N.
AU - Roddam, Andrew W.
AU - Rinaldi, Sabina
AU - Egevad, Lars
AU - Gann, Peter H.
AU - Rohrmann, Sabine
AU - Linseisen, Jakob
AU - Pischon, Tobias
AU - Boeing, Heiner
AU - Johnsen, Nina Føns
AU - Tjønneland, Anne
AU - Overvad, Kim
AU - Kiemeney, Lambertus
AU - Bueno-De-Mesquita, H. Bas
AU - Bingham, Sheila
AU - Khaw, Kay Tee
AU - Tumino, Rosario
AU - Sieri, Sabina
AU - Vineis, Paolo
AU - Palli, Domenico
AU - Quirós, José Ramón
AU - Ardanaz, Eva
AU - Chirlaque, Maria Dolores
AU - Larrañaga, Nerea
AU - Gonzalez, Carlos
AU - Sanchez, Maria José
AU - Trichopoulou, Antonia
AU - Bikou, Chrysa
AU - Trichopoulos, Dimitrios
AU - Stattin, Pär
AU - Jenab, Mazda
AU - Ferrari, Pietro
AU - Slimani, Nadia
AU - Riboli, Elio
AU - Kaaks, Rudolf
PY - 2007/9/15
Y1 - 2007/9/15
N2 - We examined the hypothesis that serum concentrations of circulating androgens and sex hormone binding globulin (SHBG) are associated with risk for prostate cancer in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition (EPIC). Concentrations of androstenedione, testosterone, androstanediol glucuronide and SHBG were measured in serum samples for 643 prostate cancer cases and 643 matched control participants, and concentrations of free testosterone were calculated. Conditional logistic regression models were used to calculate odds ratios for risk of prostate cancer in relation to the serum concentration of each hormone. After adjustment for potential confounders, there was no significant association with overall risk for prostate cancer for serum total or free testosterone concentrations (highest versus the lowest thirds: OR, 1.02; 95% CI, 0.73-1.41 and OR, 1.07, 95% CI, 0.74-1.55, respectively) or for other androgens or SHBG. Subgroup analyses showed significant heterogeneity for androstenedione by cancer stage, with a significant inverse association of androstenedione concentration and risk for advanced prostate cancer. There were also weak positive associations between free testosterone concentration and risk for total prostate cancer among younger men and risk for high-grade disease. In summary, in this large nested case-control study, concentrations of circulating androgens or SHBG were not strongly associated with risk for total prostate cancer. However, our findings are compatible with a positive association of free testosterone with risk in younger men and possible heterogeneity in the association with androstenedione concentration by stage of disease; these findings warrant further investigation.
AB - We examined the hypothesis that serum concentrations of circulating androgens and sex hormone binding globulin (SHBG) are associated with risk for prostate cancer in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition (EPIC). Concentrations of androstenedione, testosterone, androstanediol glucuronide and SHBG were measured in serum samples for 643 prostate cancer cases and 643 matched control participants, and concentrations of free testosterone were calculated. Conditional logistic regression models were used to calculate odds ratios for risk of prostate cancer in relation to the serum concentration of each hormone. After adjustment for potential confounders, there was no significant association with overall risk for prostate cancer for serum total or free testosterone concentrations (highest versus the lowest thirds: OR, 1.02; 95% CI, 0.73-1.41 and OR, 1.07, 95% CI, 0.74-1.55, respectively) or for other androgens or SHBG. Subgroup analyses showed significant heterogeneity for androstenedione by cancer stage, with a significant inverse association of androstenedione concentration and risk for advanced prostate cancer. There were also weak positive associations between free testosterone concentration and risk for total prostate cancer among younger men and risk for high-grade disease. In summary, in this large nested case-control study, concentrations of circulating androgens or SHBG were not strongly associated with risk for total prostate cancer. However, our findings are compatible with a positive association of free testosterone with risk in younger men and possible heterogeneity in the association with androstenedione concentration by stage of disease; these findings warrant further investigation.
KW - Androgen
KW - EPIC
KW - Prospective
KW - Prostate cancer
KW - Serum
UR - http://www.scopus.com/inward/record.url?scp=34548083070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548083070&partnerID=8YFLogxK
U2 - 10.1002/ijc.22814
DO - 10.1002/ijc.22814
M3 - Article
C2 - 17514649
AN - SCOPUS:34548083070
VL - 121
SP - 1331
EP - 1338
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 6
ER -